The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Cited by
Sorted by citations
Items 701–800 of 1,029
Active Cellular and Subcellular Targeting of Nanoparticles for Drug Delivery
Nag, O. K., & Delehanty, J. B. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100543 · Cited by 121
“The major driving force for the use of NPs for improved drug delivery arises from the physicochemical properties of NPs that have much to offer in the improvement of drug efficacy [1,11].”
BackgroundBiological effects of formation of protein corona onto nanoparticles
Mishra, R. K., Ahmad, A., Vyawahare, A., Alam, P., Khan, T. H., & Khan, R. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.152 · Cited by 118
Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications
Liu, M., Fang, X., Yang, Y., & Wang, C. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.701504 · Cited by 121
“Since these biological barriers help the biological system to maintain controlled and ordered material transport, the target tissue and cell penetration of foreign NPs remains one of the major challenges for therapeutic applications (Blanco et al., 2015).”
BackgroundRegulating trained immunity with nanomedicine
van Leent, M. M. T., Priem, B., Schrijver, D. P., de Dreu, A., Hofstraat, S. R. J., Zwolsman, R. C., Beldman, T. J., Netea, M. G., & Mulder, W. J. M. (2022) · Nature Reviews Materials · doi:10.1038/s41578-021-00413-w · Cited by 117
RETRACTED: An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment
Dristant, U., Mukherjee, K., Saha, S., & Maity, D. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231152083 · Cited by 120
“They must overcome the MPS’s opsonization and sequestration barriers in addition to their other strengths.(88)”
BackgroundRetractedNanomaterials engineering for drug delivery: a hybridization approach
Mohammadi, M. R., Nojoomi, A., Mozafari, M., Dubņika, A., Inayathullah, M., & Rajadas, J. (2017) · Journal of Materials Chemistry B · doi:10.1039/c6tb03247h · Cited by 113
Zhang, R., Li, J., Zhang, T., Amini, M. A., He, C., Lu, B., Ahmed, T., Lip, H., Rauth, A. M., & Wu, X. Y. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.33 · Cited by 112
3D printed personalized magnetic micromachines from patient blood–derived biomaterials
Ceylan, H., Dogan, N. O., Yasa, I. C., Musaoğlu, M. N., Kulali, Z., & Sitti, M. (2021) · Science Advances · doi:10.1126/sciadv.abh0273 · Cited by 114
Qu, Y., Chu, B., Xue, W., Chen, Y., Yang, Y. S., Hu, D., Huang, J., Wang, F., Chen, M., Zheng, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202107883 · Cited by 110
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy
Vincent, M. P., Navidzadeh, J. O., Bobbala, S. K. R., & Scott, E. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.006 · Cited by 117
Wang, B., Tang, M., Yuan, Z., Li, Z., Hu, B., Bai, X., Chu, J., Xu, X., & Zhang, X.-Q. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.026 · Cited by 112
“…for improving drug delivery across the BBB, but limited success has been achieved in the translation from bench to bedside due to complicated production procedures, low delivery efficacy, lack of specificity, and uncertain safety issues associated with nanomaterials and surfactants [20 – 22].”
BackgroundFrézard, F., Aguiar, M. G., Ferreira, L. A. M., Ramos, G. S., Santos, T. T. O., Borges, G. S. M., Vallejos, V. M. R., & de Morais, H. L. O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010099 · Cited by 118
Zeng, W., Li, Z., Huang, Q., Ding, C., Li, Y., Wang, W., Shi, Z., Yang, Y., Chen, H., Mei, L., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202307241 · Cited by 111
Machine learning-guided high throughput nanoparticle design
Ortiz‐Perez, A., van Tilborg, D., van der Meel, R., Grisoni, F., & Albertazzi, L. (2024) · Digital Discovery · doi:10.1039/d4dd00104d · Cited by 131
Angioletti‐Uberti, S. (2017) · npj Computational Materials · doi:10.1038/s41524-017-0050-y · Cited by 111
Yu, L., Dong, A., Guo, R., Yang, M., Deng, L., & Zhang, J. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00379 · Cited by 109
Programmed Nanoparticle‐Loaded Nanoparticles for Deep‐Penetrating 3D Cancer Therapy
Kim, J., Jo, C., Lim, W., Jung, S., Lee, Y. M., Lim, J., Lee, H., Lee, J., & Kim, W. J. (2018) · Advanced Materials · doi:10.1002/adma.201707557 · Cited by 113
Magnetite-Gold nanohybrids as ideal all-in-one platforms for theranostics
Efremova, M. V., Naumenko, V., Spasova, M., Garanina, A. S., Abakumov, M. A., Blokhina, A. D., Melnikov, P., Prelovskaya, A. O., Heidelmann, M., Li, Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29618-w · Cited by 113
Aguilera, G., Berry, C. C., West, R. M., Gonzalez-Monterrubio, E., Ángulo-Molina, A., Arias-Carrión, Ó., & Mendéz-Rojas, M. A. (2018) · Nanoscale Advances · doi:10.1039/c8na00010g · Cited by 110
Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development
Rawal, M., Singh, A., & Amiji, M. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2692-6 · Cited by 112
“(20) This section will focus on some key aspects of nanoparticle characterization for their physicochemical and biological properties; and emphasize on the role of these validations for obtaining a quality product for successful clinical translation.”
BackgroundInfluentialShi, S., Li, T., Wen, X., Wu, S. Y., Xiong, C., Zhao, J., Lincha, V. R., Chow, D. S., Liu, Y., Sood, A. K., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00587 · Cited by 109
Orooji, Y., Mortazavi‐Derazkola, S., Ghoreishi, S. M., Amiri, M., & Salavati‐Niasari, M. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.123140 · Cited by 110
RetractedShim, M. K., Moon, Y., Yang, S., Kim, J., Cho, H., Lim, S., Yoon, H. Y., Seong, J., & Kim, K. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120347 · Cited by 111
Li, J., Zhang, Y., Dong, P.-Y., Yang, G.-M., & Gurunathan, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115087 · Cited by 115
Albumin-coated nanocrystals for carrier-free delivery of paclitaxel
Park, J., Sun, B., & Yeo, Y. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.040 · Cited by 110
“With traditional top-down or bottom-up methods, it is difficult to reduce the particle size to below 200 nm, the upper size limit for preferential extravasation through the leaky tumor vasculature [20].”
Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications
Hidalgo, A., Cruz, A., & Pérez‐Gil, J. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.04.019 · Cited by 111
Sun, X. J., Zhang, G., Du, R., Xu, R. F., Zhu, D., Qian, J., Bai, G., Yang, C., Zhang, Z., Zhang, X., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.004 · Cited by 114
Mou, Q., Ma, Y., Ding, F., Gao, X., Yan, D., Zhu, X., & Zhang, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13875 · Cited by 109
Peltek, O. O., Muslimov, A. R., Zyuzin, M. V., & Timin, A. S. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0524-9 · Cited by 116
Duong, H. T. T., Thambi, T., Yin, Y., Kim, S., Nguyen, T. L., Phan, V. H. G., Kim, J., Jeong, J. H., & Lee, D. S. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119599 · Cited by 108
Mechanistic Understanding of the Biological Responses to Polymeric Nanoparticles
Kenry, K., Yeo, T., Manghnani, P. N., Middha, E., Pan, Y., Chen, H., Lim, C. T., & Liu, B. (2020) · ACS Nano · doi:10.1021/acsnano.9b10195 · Cited by 112
Wang, Y., Shahi, P. K., Xie, R., Zhang, H., Abdeen, A. A., Yodsanit, N., Ma, Z., Saha, K., Pattnaik, B. R., & Gong, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.052 · Cited by 110
Protein-based nanomaterials and nanosystems for biomedical applications: A review
Ding, S., Zhang, N., Lyu, Z., Zhu, W., Chang, Y., Hu, X., Du, D., & Lin, Y. (2020) · Materials Today · doi:10.1016/j.mattod.2020.11.015 · Cited by 111
Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy
Pan, H., Zheng, M., Ma, A.-Q., Liu, L., & Cai, L. (2021) · Advanced Materials · doi:10.1002/adma.202100241 · Cited by 109
Lin, H., Yu, Y., Zhu, L., Lai, N., Zhang, L., Guo, Y., Lin, X., Yang, D., Ren, N., Zhu, Z., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102601 · Cited by 111
Song, W., Muthana, M., Mukherjee, J., Falconer, R. J., Biggs, C. A., & Zhao, X. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00153 · Cited by 108
Advanced smart-photosensitizers for more effective cancer treatment
Park, W., Cho, S., Han, J., Shin, H., Na, K., Lee, B., & Kim, D. (2017) · Biomaterials Science · doi:10.1039/c7bm00872d · Cited by 111
Malvajerd, S. S., Izadi, Z., Azadi, A., Kurd, M., Derakhshankhah, H., Sharifzadeh, M. S., Javar, H. A., & Hamidi, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190083 · Cited by 112
“Thenanoparticlessizeisoneoftheimportant parametersaffectingtheopsonizationprocessand thenatureofproteincorona[69,70].”
The role of critical micellization concentration in efficacy and toxicity of supramolecular polymers
Su, H., Wang, F., Ran, W., Zhang, W., Dai, W., Wang, H., Anderson, C. F., Wang, Z., Zheng, C., Zhang, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913655117 · Cited by 108
“The use of the OEG segment to modify the side chain of lysine endows a nonionic and neutral surface chemistry to the resultant SPs, so as to reduce protein absorption and increase circulation half-lives (45).”
BackgroundWang, D., Wu, H., Yang, G., Qian, C., Gu, L., Wang, H., Zhou, W., Liu, J., Wu, Y., Zhang, X., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c05499 · Cited by 109
Shahab, M. S., Rizwanullah, M., Alshehri, S., & Imam, S. S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.09.185 · Cited by 108
Zhu, Y., Yang, Z., Dong, Z., Gong, Y., Hao, Y., Tian, L., Yang, X., Liu, Z., & Feng, L. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00549-4 · Cited by 108
Haider, M. A., Zaki, K. Z., Hamshary, M. R. E., Hussain, Z., Orive, G., & Ibrahim, H. O. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.008 · Cited by 110
Nanotools for Sepsis Diagnosis and Treatment
Papafilippou, L., Claxton, A., Dark, P., Kostarelos, K., & Hadjidemetriou, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001378 · Cited by 118
Ultra-small lipid–polymer hybrid nanoparticles for tumor-penetrating drug delivery
Dehaini, D., Fang, R. H., Luk, B. T., Pang, Z., Hu, C. J., Kroll, A. V., Yu, C. L., Gao, W., & Zhang, L. (2016) · Nanoscale · doi:10.1039/c6nr04091h · Cited by 107
Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease
Wang, J., Masehi-Lano, J. J., & Chung, E. J. (2017) · Biomaterials Science · doi:10.1039/c7bm00271h · Cited by 107
Modular assembly of proteins on nanoparticles
Ma, W., Saccardo, A., Roccatano, D., Aboagye-Mensah, D., Alkaseem, M., Jewkes, M., Nezza, F. D., Baron, M. G., Soloviev, M., & Ferrari, E. (2018) · Nature Communications · doi:10.1038/s41467-018-03931-4 · Cited by 110
Sato, Y., Kinami, Y., Hashiba, K., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.006 · Cited by 112
Amphotericin B Loaded Polymeric Nanoparticles for Treatment of Leishmania Infections
Saqib, M., Bhatti, A. S. A., Ahmad, N. M., Ahmed, N., Shahnaz, G., Lebaz, N., & Elaı̈ssari, A. (2020) · Nanomaterials · doi:10.3390/nano10061152 · Cited by 107
“The use of PCL enables them to enhance the nanoparticles in order to entrap drug molecules, and it also enhances aqueous solubility, promoting drug escape from the nanoparticles [23].”
BackgroundMethodFeng, X., Xu, W., Liu, J., Li, D., Gao, L., Ding, J., & Chen, X. (2020) · 中国科学通报：英文版 · doi:10.1016/j.scib.2020.07.013 · Cited by 106
“This result is consistent with previous findings that nanoparticles have preferential accumulation at mononuclear phagocytic system organs, including the liver, owing to their opsonization [33].”
ResultpH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
Yan, Y., & Ding, H. (2020) · Nanomaterials · doi:10.3390/nano10081613 · Cited by 113
Xiao, W., Song, M., Li, W., Huang, J., Yang, G. Y., & Wang, Y. (2021) · Theranostics · doi:10.7150/thno.59342 · Cited by 108
“By means of targeted and stimulus-responsive capacities, nanocarriers can help transport therapeutic agents across a series of physiological barriers, thus successfully completing tumor microenvironmental delivery (the penetration of stromal barriers) and intracellular delivery (lysosomal escape, cytoplasmic release o…”
BackgroundAnti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 119
Morphologic design of nanostructures for enhanced antimicrobial activity
Sayed, F. A.-Z., Eissa, N. G., Shen, Y., Hunstad, D. A., Wooley, K. L., & Elsabahy, M. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01733-x · Cited by 112
“, circulation lifetime), targeting, biodistribution, cellular uptake, and subsequent cellular trafficking are profoundly influenced by physicochemical characteristics of nanoparticles, such as morphology, size, and aspect ratio [37, 38].”
BackgroundNucleic acid drug vectors for diagnosis and treatment of brain diseases
Lü, Z., Shen, J., Yang, H. J., Wang, J., Zhao, R., Zhang, T.-L., Guo, J. R., & Zhang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01298-z · Cited by 116
Developments in nanotechnology approaches for the treatment of solid tumors
Venturini, J., Chakraborty, A., Baysal, M. A., & Tsimberidou, A. M. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00656-1 · Cited by 123
“PEG forms a hydrophilic and sterically repulsive layer that reduces protein adsorption (opsonization), a mechanism by which nanoparticles are marked for clearance by the mononuclear phagocyte system, particularly macrophages in the liver and spleen [30].”
Zhu, Q., Chen, X., Xu, X., Zhang, Y., Zhang, C., & Mo, R. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707371 · Cited by 105
Lipid coated chitosan-DNA nanoparticles for enhanced gene delivery
Baghdan, E., Pinnapireddy, S. R., Strehlow, B., Engelhardt, K. H., Schäfer, J., & Bakowsky, U. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.045 · Cited by 110
Ingato, D., Edson, J. A., Zakharian, M., & Kwon, Y. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b05377 · Cited by 108
Mariadoss, A. V. A., Vinayagam, R., Senthilkumar, V., Paulpandi, M., Murugan, K., Xu, B., Muthukaliannan, G. K., Kotakadi, V. S., & David, E. K. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.031 · Cited by 106
Yongvongsoontorn, N., Chung, J. E., Gao, S. J., Bae, K. H., Yamashita, A., Tan, M., Ying, J. Y., & Kurisawa, M. (2019) · ACS Nano · doi:10.1021/acsnano.9b00467 · Cited by 106
A Single Molecule Drug Targeting Photosensitizer for Enhanced Breast Cancer Photothermal Therapy
Zou, Y., Li, M., Xiong, T., Zhao, X., Du, J., Fan, J., & Peng, X. (2020) · Small · doi:10.1002/smll.201907677 · Cited by 106
Xiong, K., Zhang, Y., Wen, Q., Luo, J., Lü, Y., Wu, Z., Wang, B., Chen, Y., Zhao, L., & Fu, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119875 · Cited by 109
DNA Nanostructures and DNA‐Functionalized Nanoparticles for Cancer Theranostics
Nicolson, F., Ali, A., Kircher, M. F., & Pal, S. (2020) · Advanced Science · doi:10.1002/advs.202001669 · Cited by 105
Cell membrane-camouflaged inorganic nanoparticles for cancer therapy
Song, W., Jia, P., Zhang, T., Dou, K., Liu, L., Ren, Y., Liu, F., Xue, J., Hasanin, M. S., Qi, H., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01475-w · Cited by 108
“(negative or neutral), NPs can enhance the accumulation of anti-cancer drugs in cancers and reduce their side effects [14].”
BackgroundHe, H., Han, Q., Wang, S., Long, M., Zhang, M., Li, Y., Zhang, Y., & Gu, N. (2023) · ACS Nano · doi:10.1021/acsnano.3c01420 · Cited by 107
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside
Abdullah, K. M., Sharma, G., Singh, A. P., & Siddiqui, J. A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02368-w · Cited by 124
“It has also been reported by recent studies that nanoparticles having a higher aspect ratio have longer circulation times with maximum tumor accumulation because they can more effectively avoid phagocytosis [95, 96].”
Wen, J., Wu, D., Qin, M., Liu, C., Wang, L., Xu, D., Vinters, H. V., Liu, Y., Kranz, E., Guan, X., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0434-z · Cited by 108
Ferreira, M. P. A., Ranjan, S. K., Kinnunen, S. M., Correia, A., Talman, V., Mäkilä, E. M., Barrios‐Lopez, B., Kemell, M., Balasubramanian, V., Salonen, J., et al. (2017) · Small · doi:10.1002/smll.201701276 · Cited by 111
Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats
Bhattacharya, S., Mondal, L., Mukherjee, B., Dutta, L., Ehsan, I., Debnath, M. C., Gaonkar, R. H., Pal, M. M., & Majumdar, S. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.05.011 · Cited by 105
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
Samanta, K., Setua, S., Kumari, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110574 · Cited by 105
Programming Drug Delivery Kinetics for Active Burst Release with DNA Toehold Switches
Xiao, M., Lai, W., Wang, F., Li, L., Fan, C., & Pei, H. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10765 · Cited by 105
Saraswat, A. L., Patki, M., Fu, Y., Barot, S., Dukhande, V. V., & Patel, K. R. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0156 · Cited by 105
Park, Y. I., Kwon, S., Lee, G., Motoyama, K., Kim, M. W., Lin, M., Niidome, T., Choi, J. H., & Lee, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.011 · Cited by 108
Quercetin nanoformulations: a promising strategy for tumor therapy
Zang, X., Cheng, M., Zhang, X., & Chen, X. (2021) · Food & Function · doi:10.1039/d1fo00851j · Cited by 106
Mao, Q., Fang, J. Y., Wang, A., Zhang, Y., Cui, C., Ye, S., Zhao, Y., Feng, Y., Li, J., & Shi, H. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109863 · Cited by 105
Sheffey, V. V., Siew, E. B., Tanner, E. E. L., & Eniola‐Adefeso, O. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101536 · Cited by 103
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
Yadav, P., Ambudkar, S. V., & Prasad, N. R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01626-z · Cited by 109
“sustained release of drugs, prevent drug metabolism and detoxification and have a long circulation time, avoiding clearance from the system and enhancing uptake within cells [98].”
BackgroundChemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106
“A wide range of drug delivery systems struggle to release their payload after internalization because of failure to escape from lysosomal compartments in which they end up after internalization [17,18].”
BackgroundDePEGylation strategies to increase cancer nanomedicine efficacy
Kong, L., Campbell, F., & Kros, A. (2018) · Nanoscale Horizons · doi:10.1039/c8nh00417j · Cited by 107
Surface-kinetics mediated mesoporous multipods for enhanced bacterial adhesion and inhibition
Zhao, T., Chen, L., Wang, P., Li, B., Lin, R., Al-Khalaf, A. A., Hozzein, W. N., Zhang, F., Li, X., & Zhao, D. (2019) · Nature Communications · doi:10.1038/s41467-019-12378-0 · Cited by 104
Nanoscale delivery systems for microRNAs in cancer therapy
Boca, S., Gulei, D., Zimța, A., Onaciu, A., Magdo, L., Țigu, A. B., Ionescu, C., Irimie, A., Buiga, R., & Berindan‐Neagoe, I. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03317-9 · Cited by 103
Chen, L., Zhao, T., Zhao, M., Wang, W., Sun, C., Liu, L., Li, Q., Zhang, F., Zhao, D., & Li, X. (2020) · Chemical Science · doi:10.1039/c9sc06260b · Cited by 104
Peng, H., Qin, Y., He, X., Li, W., & Zhang, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c00468 · Cited by 104
LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy
d’Avanzo, N., Torrieri, G., Figueiredo, P., Celia, C., Paolino, D., Correia, A., Moslova, K., Teesalu, T., Fresta, M., & Santos, H. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120346 · Cited by 107
“All drug-loaded liposomes, both functionalized and bare ones, exhibited the physicochemical characteristics suitable for their systemic use as drug delivery systems for anticancer therapy: (i) an average diameter below than 200 nm suggesting their ability to penetrate intact through fenestrated vasculature of neo-form…”
BackgroundMeng, J., Yang, X. F., Huang, J., Tuo, Z., Hu, Y., Liao, Z., Tian, Y., Deng, S., Deng, Y., Zhou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300517 · Cited by 106
Size Dependent Kinetics of Gold Nanorods in EPR Mediated Tumor Delivery
Tong, X., Wang, Z., Sun, X., Song, J., Jacobson, O., Niu, G., Kiesewetter, D. O., & Chen, X. S. (2016) · Theranostics · doi:10.7150/thno.17098 · Cited by 103
“However, therapy efficacy requires efficient intravascular delivery and tumor extravasation of AuNR, it is extremely important to understand the effect of size and aspect ratio of the AuNRs on its kinetics and tissue uptake during intravascular circulation, MPS elimination and tumor accumulation.”
BackgroundInfluentialWavikar, P., Pai, R. V., & Vavia, P. R. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.08.024 · Cited by 103
Li, M., Luo, Z. Y., & Zhao, Y. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b03924 · Cited by 107
Design strategies for physical-stimuli-responsive programmable nanotherapeutics
Sahle, F. F., Gulfam, M., & Lowe, T. L. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.04.003 · Cited by 103
Yang, S., Dai, L., Sun, C., & Gao, Y. (2018) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2018.07.015 · Cited by 103
Finnegan, J. R., He, X., Street, S. T. G., Garcia-Hernandez, J. D., Hayward, D. W., Harniman, R. L., Richardson, R. M., Whittell, G. R., & Manners, I. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09861 · Cited by 105
“6,18,19 22 This yields low dis-persity fibers of a length controlled by the ratio of added BCP to seed micelles.”
BackgroundRad, A. T., Chen, C., Aresh, W., Xia, Y., Lai, P., & Nieh, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b21609 · Cited by 101
Hosseini, S. M., Abbasalipourkabir, R., Jalilian, F. A., Asl, S. S., Farmany, A., Roshanaei, G., & Arabestani, M. R. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0504-8 · Cited by 103
“Targeted drug delivery system can be considered as an appropriate tool to overcome such problems [8].”
BackgroundFrom Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 102
Nanoparticles approach to eradicate bacterial biofilm-related infections: A critical review
Al-Wrafy, F. A., Al-Gheethi, A. A. S., Ponnusamy, S. K., Noman, E. A., & Fattah, S. A. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.132603 · Cited by 103
Chen, L., Zhou, Z., Hu, C., Maitz, M. F., Yang, L., Luo, R., & Wang, Y. (2022) · Research · doi:10.34133/2022/9845459 · Cited by 110
“With the rapid progress in materials and chemistry, nanoparticles (NPs) -mediated drug delivery systems have achieved considerable improvement, but still are difficult to obtain clinical approval.[18-23] Conventional nanoparticle-based drug delivery systems have shortcomings that they rapidly undergo immune clearance,…”
BackgroundPolymeric particle-based therapies for acute inflammatory diseases
Brannon, E. R., Guevara, M. V., Pacifici, N. J., Lee, J. K., Lewis, J. S., & Eniola‐Adefeso, O. (2022) · Nature Reviews Materials · doi:10.1038/s41578-022-00458-5 · Cited by 103
Biddeci, G., Spinelli, G., Colomba, P., & Blasi, F. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911518 · Cited by 103
Nanodiamond-enhanced MRI via in situ hyperpolarization
Waddington, D. E. J., Sarracanie, M., Zhang, H., Salameh, N., Glenn, D. R., Rej, E., Gaebel, T., Boele, T., Walsworth, R. L., Reilly, D. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15118 · Cited by 102
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
